# Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.

> **NCT06364267** · PHASE2 · RECRUITING · sponsor: **Andrea DeCensi** · enrollment: 140 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tamoxifen 10 MG
- **DRUG:** Exemestane 25 MG

## Key facts

- **NCT ID:** NCT06364267
- **Lead sponsor:** Andrea DeCensi
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06364267

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06364267, "Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06364267. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*